Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies
for the Japan Study Group for Cell Therapy, Transplantation (JSCT)
Dive into the research topics of 'Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies'. Together they form a unique fingerprint.